Englander Institute for Precision Medicine

Publications

Found 805 results
Author Title Type [ Year(Asc)]
2022
Klapp V, Galluzzi L.  2022.  Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.. Trends Cancer. 8(1):1-3.
Batra R, Whalen W, Alvarez-Mulett S, Gómez-Escobar LG, Hoffman KL, Simmons W, Harrington J, Chetnik K, Buyukozkan M, Benedetti E et al..  2022.  Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. medRxiv.
Batra R, Whalen W, Alvarez-Mulett S, Gómez-Escobar LG, Hoffman KL, Simmons W, Harrington J, Chetnik K, Buyukozkan M, Benedetti E et al..  2022.  Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. PLoS Pathog. 18(9):e1010819.
Jiménez-Cortegana C, Galassi C, Klapp V, Gabrilovich DI, Galluzzi L.  2022.  Myeloid-Derived Suppressor Cells and Radiotherapy.. Cancer Immunol Res. 10(5):545-557.
Podaza E, Kuo H-H, Nguyen J, Elemento O, M Martin L.  2022.  Next generation patient derived tumor organoids.. Transl Res. 250:84-97.
Hu Y, Bloy N, Elemento O, Buqué A.  2022.  Nicotinamide drives T cell activation in the mammary tumor microenvironment.. J Transl Med. 20(1):251.
Tong L, Jiménez-Cortegana C, Tay AHM, Wickström S, Galluzzi L, Lundqvist A.  2022.  NK cells and solid tumors: therapeutic potential and persisting obstacles.. Mol Cancer. 21(1):206.
Drozdz MM, Doane AS, Alkallas R, Desman G, Bareja R, Reilly M, Bang J, Yusupova M, You J, Eraslan Z et al..  2022.  A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation.. Cell Rep. 40(13):111412.
Lorenzin F, Demichelis F.  2022.  Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.. Cancers (Basel). 14(5)
Clement CC, Osan J, Buqué A, Nanaware PP, Chang Y-C, Perino G, Shetty M, Yamazaki T, Tsai WLi, Urbanska AM et al..  2022.  PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.. Sci Immunol. 7(74):eabl3795.
Powles T, Park SHoon, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A et al..  2022.  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.. Future Oncol. 18(19):2361-2371.
Álvarez-Abril B, García-Martínez E, Galluzzi L.  2022.  Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.. Oncoimmunology. 11(1):2052411.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA et al..  2022.  Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. Nat Commun. 13(1):1878.
Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JLyun, Fléchon A, Roubaud G, Pouessel D, Zagonel V, Calabrò F et al..  2022.  Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. Eur J Cancer. 163:55-65.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A, Sternberg CN, O'Donnell PH et al..  2022.  Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. Clin Cancer Res. 28(10):2050-2060.
Sato A, Bloy N, Galassi C, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Yamazaki T, Petroni G, Galluzzi L et al..  2022.  Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis.. Methods Cell Biol. 172:115-134.
Petroni G, Cantley LC, Santambrogio L, Formenti SC, Galluzzi L.  2022.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.. Nat Rev Clin Oncol. 19(2):114-131.
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao XL, Guo H, Sandström P et al..  2022.  Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.. Future Oncol. 18(1):35-45.
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J et al..  2022.  Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).. Prostate Cancer Prostatic Dis. 25(2):306-313.
Gajic ZZ, Deshpande A, Legut M, Imielinski M, Sanjana NE.  2022.  Recurrent somatic mutations as predictors of immunotherapy response.. Nat Commun. 13(1):3938.
Han Y, Lee T, He Y, Raman R, Irizarry A, M Martin L, Giaccone G.  2022.  The regulation of CD73 in non-small cell lung cancer.. Eur J Cancer. 170:91-102.
Montrose DC, Galluzzi L.  2022.  Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer.. Cancer Res. 82(8):1464-1466.
Ullmann TM, Thiesmeyer JW, Lee YJoo, Beg S, Mosquera JMiguel, Elemento O, Fahey TJ, Scognamiglio T, Houvras Y.  2022.  RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype.. Ann Surg Oncol.
Galassi C, Ruan Y, Sato A, Jiménez-Cortegana C, Klapp V, Bloy N, Guilbaud E, Petroni G, Buqué A, Galluzzi L et al..  2022.  RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells.. Methods Cell Biol. 172:145-161.
Laurent P, Yang C, Rendeiro AF, Nilsson-Payant BE, Carrau L, Chandar V, Bram Y, tenOever BR, Elemento O, Ivashkiv LB et al..  2022.  Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19.. Sci Immunol. 7(75):eadd4906.